McKelligon Brian's Form 4/A amendment
AmendedAkoya Biosciences, Inc. (AKYA) · filed Mar 22, 2024
- Accession no.
- 0001104659-24-037977
- Filed
- Mar 22, 2024, 5:51 PM ET
- Trade date
- Mar 13, 2024
- Filing delay
- 9 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Mar 14, 2024
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $37.0K. It was filed 9 days after the trade.
This amendment replaces 0001104659-24-034668 (filed Mar 14, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McKelligon BrianCIK 0001857447 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | MOption exerciseAcquired | +7,500 | $0.303 | +$2,272.5 | 239,368 | Direct | |
| Mar 13, 2024 | Common Stock | SSaleDisposed | −7,500 | $4.94F2 | −$37,042.5 | 231,868 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 298,129 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 to $5.08, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
Referenced by the price of 1 transaction in Table I.
- F3
The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on August 14, 2018, subject to reporting person's continuous employment.